Molecular characterization of 103 ovarian serous and mucinous tumors

Ildikó Vereczkey, Orsolya Serester, J. Dobos, M. Gallai, Orsolya Szakács, Z. Szentirmay, Erika Tóth

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60% of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a "dualistic" model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100% of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.

Original languageEnglish
Pages (from-to)551-559
Number of pages9
JournalPathology and Oncology Research
Volume17
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Neoplasms
Mutation
p53 Genes
Carcinogenesis
Carcinoma
Freezing
Real-Time Polymerase Chain Reaction
Phosphotransferases
Immunohistochemistry
Genes

Keywords

  • Borderline
  • Molecular
  • Mucinous
  • Ovary
  • Pathogenesis
  • Serous

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Molecular characterization of 103 ovarian serous and mucinous tumors. / Vereczkey, Ildikó; Serester, Orsolya; Dobos, J.; Gallai, M.; Szakács, Orsolya; Szentirmay, Z.; Tóth, Erika.

In: Pathology and Oncology Research, Vol. 17, No. 3, 09.2011, p. 551-559.

Research output: Contribution to journalArticle

Vereczkey, Ildikó ; Serester, Orsolya ; Dobos, J. ; Gallai, M. ; Szakács, Orsolya ; Szentirmay, Z. ; Tóth, Erika. / Molecular characterization of 103 ovarian serous and mucinous tumors. In: Pathology and Oncology Research. 2011 ; Vol. 17, No. 3. pp. 551-559.
@article{6b69aa3644004bfcb982ba8127070668,
title = "Molecular characterization of 103 ovarian serous and mucinous tumors",
abstract = "The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60{\%} of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a {"}dualistic{"} model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100{\%} of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.",
keywords = "Borderline, Molecular, Mucinous, Ovary, Pathogenesis, Serous",
author = "Ildik{\'o} Vereczkey and Orsolya Serester and J. Dobos and M. Gallai and Orsolya Szak{\'a}cs and Z. Szentirmay and Erika T{\'o}th",
year = "2011",
month = "9",
doi = "10.1007/s12253-010-9345-8",
language = "English",
volume = "17",
pages = "551--559",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Molecular characterization of 103 ovarian serous and mucinous tumors

AU - Vereczkey, Ildikó

AU - Serester, Orsolya

AU - Dobos, J.

AU - Gallai, M.

AU - Szakács, Orsolya

AU - Szentirmay, Z.

AU - Tóth, Erika

PY - 2011/9

Y1 - 2011/9

N2 - The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60% of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a "dualistic" model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100% of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.

AB - The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60% of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a "dualistic" model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100% of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.

KW - Borderline

KW - Molecular

KW - Mucinous

KW - Ovary

KW - Pathogenesis

KW - Serous

UR - http://www.scopus.com/inward/record.url?scp=80052736732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052736732&partnerID=8YFLogxK

U2 - 10.1007/s12253-010-9345-8

DO - 10.1007/s12253-010-9345-8

M3 - Article

C2 - 21136228

AN - SCOPUS:80052736732

VL - 17

SP - 551

EP - 559

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -